InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.550 0.005 (0.32%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,524 Grant of Patents by the US Patent Office 8 Jul 2026 9:01AM $1.535 $1.550 risen by 0.98%
$1,524 Appointment of Chief Financial Officer 7 Jul 2026 8:21AM $1.555 $1.550 fallen by 0.32%
$1,524 Notification of cessation of securities - PYC 18 Jun 2026 8:26AM $1.335 $1.550 risen by 16.10%
$1,524 Becoming a substantial holder 16 Jun 2026 4:29PM $1.270 $1.550 risen by 22.05%
$1,524 Company Secretary Appointment/Resignation 15 Jun 2026 3:01PM $1.225 $1.550 risen by 26.53%
$1,524 Notice of General Meeting/Proxy Form 12 Jun 2026 3:55PM $1.215 $1.550 risen by 27.57%
$1,524 Change to CEO remuneration 26 May 2026 7:23PM $1.380 $1.550 risen by 12.32%
$1,524 2026 Q2 Investor Webinar Presentation 22 May 2026 9:17AM $1.305 $1.550 risen by 18.77%
$1,524 Ceasing to be a substantial holder 18 May 2026 7:06PM $1.325 $1.550 risen by 16.98%
$1,524 Investor Webinar 12 May 2026 9:07AM $1.265 $1.550 risen by 22.53%
$1,524 Notification of cessation of securities - PYC 11 May 2026 6:56PM $1.265 $1.550 risen by 22.53%
$1,524 PKD - Initiation of Multiple Dose Clinical Trial 7 May 2026 9:03AM $1.165 $1.550 risen by 33.05%
$1,524 Presentation of Ophthalmology Clinical Trial Data at ARVO 4 May 2026 9:14AM $1.225 $1.550 risen by 26.53%
$1,524 Exercise of Options and Cleansing Notice 28 Apr 2026 6:44PM $1.305 $1.550 risen by 18.77%
$1,524 Application for quotation of securities - PYC 28 Apr 2026 6:34PM $1.305 $1.550 risen by 18.77%
$1,524 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:12AM $1.310 $1.550 risen by 18.32%
$1,524 Orphan Drug Designation Granted for RP11 by EMA 27 Apr 2026 9:48AM $1.295 $1.550 risen by 19.69%
$1,524 ADOA Program - SRC Approve Progression to Multi-Dose Study 15 Apr 2026 10:53AM $1.210 $1.550 risen by 28.10%
$1,524 Change in substantial holding 1 Apr 2026 8:25PM $1.165 $1.550 risen by 33.05%
$1,524 Change of Director's Interest Notice RH 27 Mar 2026 1:17PM $1.113 $1.550 risen by 39.33%
$1,524 PKD - Presentation at World Congress of Nephrology 27 Mar 2026 9:58AM $1.170 $1.550 risen by 32.48%
$1,524 ADOA Program - Presentation at NANOS 2026 24 Mar 2026 9:01AM $1.200 $1.550 risen by 29.17%
$1,524 Regulatory Alignment on Registrational Trial Requirements 16 Mar 2026 9:19AM $1.415 $1.550 risen by 9.54%
$1,524 Change of Director's Interest Notice RH IC 10 Mar 2026 6:41PM $1.470 $1.550 risen by 5.44%
$1,524 Application for quotation of securities - PYC 9 Mar 2026 7:55PM $1.480 $1.550 risen by 4.73%

1 - 25 of 923 results

Page 1 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.